The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Диагностика деменции вследствие болезни Альцгеймера: рекомендации рабочих групп Национального института старения и Ассоциации Альцгеймера по руководящим принципам диагностики болезни Альцгеймера
Bradley T. Hyman, Guy M. McKhann, John C. Morris, Philip Scheltens, David S. Knopman, Howard Chertkow, Clifford R. Jack, Claudia H. Kawas, William E. Klunk, Walter J. Koroshetz, Jennifer J. Manly, Richard Mayeux, Richard C. Mohs, Martin N. Rossor, María C. Carrillo, Bill Thies, Sandra Weıntraub, Creighton H. Phelps
2011-04-22

Alzheimer's disease dementiabiomarker evidencediagnostic criteria revisionprobable and possible AD dementia
The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of revising the 1984 criteria for Alzheimer's disease (AD) dementia. The workgroup sought to ensure that the revised criteria would be flexible enough to be used by both general healthcare providers without access to neuropsychological testing, advanced imaging, and cerebrospinal fluid measures, and specialized investigators involved in research or in clinical trial studies who would have these tools available. We present criteria for all-cause dementia and for AD dementia. We retained the general framework of probable AD dementia from the 1984 criteria. On the basis of the past 27 years of experience, we made several changes in the clinical criteria for the diagnosis. We also retained the term possible AD dementia, but redefined it in a manner more focused than before. Biomarker evidence was also integrated into the diagnostic formulations for probable and possible AD dementia for use in research settings. The core clinical criteria for AD dementia will continue to be the cornerstone of the diagnosis in clinical practice, but biomarker evidence is expected to enhance the pathophysiological specificity of the diagnosis of AD dementia. Much work lies ahead for validating the biomarker diagnosis of AD dementia.
1
Biomarker evidence (imaging and cerebrospinal fluid measures) is integrated into diagnostic formulations for probable and possible AD dementia for research settings.
2
Core clinical criteria remain the cornerstone for clinical practice, while biomarkers are expected to enhance pathophysiological specificity but require further validation.
3
New criteria are designed to be flexible for both general clinicians without advanced testing and specialized researchers with imaging and CSF biomarkers.
4
Revised diagnostic criteria for Alzheimer's disease (AD) dementia update the 1984 criteria while keeping the probable AD dementia framework.
5
The term 'possible AD dementia' is retained but redefined with a more focused definition than in 1984.

Diagnostic criteria for dementia due to Alzheimer's disease (AD dementia)

Recommendations and revisions to clinical and research diagnostic criteria, including integration of biomarkers and definitions of probable and possible AD dementia to improve diagnostic specificity and applicability across clinical and research settings

Publication Details
Publication Date
2011-04-22
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Bradley T. Hyman
Guy M. McKhann
John C. Morris
Philip Scheltens
David S. Knopman
Howard Chertkow
Clifford R. Jack
Claudia H. Kawas
William E. Klunk
Walter J. Koroshetz
Jennifer J. Manly
Richard Mayeux
Richard C. Mohs
Martin N. Rossor
María C. Carrillo
Bill Thies
Sandra Weıntraub
Creighton H. Phelps
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat
Make a presentation
100%